Progesterone, progestins and the breast in menopause treatment

References

• IBIS Risk Calculator [Internet]. Available from: http://www.ems-trials.org/riskevaluator/
   Google Scholar
• Gompel A, Plu-Bureau G. Is the decrease in breast cancer incidence related to a decrease in postmenopausal hormone therapy? Ann N Y Acad Sci 2010;1205:268–76
   PubMed Web of Science ®Google Scholar
• Tokunaga M, Norman JE, Asano M, et al. Malignant breast tumors among atomic bomb survivors, Hiroshima and Nagasaki, 1950–74. J Natl Cancer Inst 1979;62:1347–59
   PubMed Web of Science ®Google Scholar
• Gonzalez-Suarez E, Jacob AP, Jones J, et al. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 2010;468:103–7
   PubMed Web of Science ®Google Scholar
• Schramek D, Leibbrandt A, Sigl V, et al. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 2010;468:98–102
   PubMed Web of Science ®Google Scholar
• Rao S, Cronin SJF, Sigl V, Penninger JM. RANKL and RANK: from mammalian physiology to cancer treatment. Trends Cell Biol 2018;28:213–23
   PubMed Web of Science ®Google Scholar
• Sarink D, Schock H, Johnson T, et al. Circulating RANKL and RANKL/OPG and breast cancer risk by ER and PR subtype: results from the EPIC cohort. Cancer Prev Res (Phila) 2017;10:525–34
   PubMed Web of Science ®Google Scholar
• Azim HA, Peccatori FA, Brohée S, et al. RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy. Breast Cancer Res 2015;17:24
   PubMed Web of Science ®Google Scholar
• Sigl V, Owusu-Boaitey K, Joshi PA, et al. RANKL/RANK control Brca1 mutation-driven mammary tumors. Cell Res 2016;26:761–74
   PubMed Web of Science ®Google Scholar
• Dressing GE, Alyea R, Pang Y, Thomas P. Membrane progesterone receptors (mPRs) mediate progestin induced antimorbidity in breast cancer cells and are expressed in human breast tumors. Horm Cancer 2012;3:101–12
   PubMed Web of Science ®Google Scholar
• Willibald M, Wurster I, Meisner C, et al. High level of progesteron receptor membrane component 1 (PGRMC 1) in tissue of breast cancer patients is associated with worse response to anthracycline-based neoadjuvant therapy. Horm Metab Res 2017;49:595–603
   PubMed Web of Science ®Google Scholar
• Neubauer H, Ma Q, Zhou J, et al. Possible role of PGRMC1 in breast cancer development. Climacteric 2013;16:509–13
   PubMed Web of Science ®Google Scholar
• Longacre TA, Bartow SA. A correlative morphologic study of human breast and endometrium in the menstrual cycle. Am J Surg Pathol 1986;10:382–93
   PubMed Web of Science ®Google Scholar
• Barrat J, de Lignières B, Marpeau L, et al. The in vivo effect of the local administration of progesterone on the mitotic activity of human ductal breast tissue. Results of a pilot study. J Gynecol Obstet Biol Reprod (Paris) 1990;19:269–74
   PubMedGoogle Scholar
• Chang KJ, Lee TT, Linares-Cruz G, Fournier S, de Ligniéres B. Influences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo. Fertil Steril 1995;63:785–91
   PubMed Web of Science ®Google Scholar
• Foidart JM, Colin C, Denoo X, et al. Estradiol and progesterone regulate the proliferation of human breast epithelial cells. Fertil Steril 1998;69:963–9
   PubMed Web of Science ®Google Scholar
• Murkes D, Conner P, Leifland K, et al. Effects of percutaneous estradiol-oral progesterone versus oral conjugated equine estrogens-medroxyprogesterone acetate on breast cell proliferation and bcl-2 protein in healthy women. Fertil Steril 2011;95:1188–91
   PubMed Web of Science ®Google Scholar
• Kaaks R, Berrino F, Key T, et al. Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). J Natl Cancer Inst 2005;97:755–65
   PubMed Web of Science ®Google Scholar
• Fortner RT, Eliassen AH, Spiegelman D, Willett WC, Barbieri RL, Hankinson SE. Premenopausal endogenous steroid hormones and breast cancer risk: results from the Nurses’ Health Study II. Breast Cancer Res 2013;15:R19
   PubMed Web of Science ®Google Scholar
• Henderson BE, Ross RK, Judd HL, Krailo MD, Pike MC. Do regular ovulatory cycles increase breast cancer risk? Cancer 1985;56:1206–8
   PubMed Web of Science ®Google Scholar
• González ER. Chronic anovulation may increase postmenopausal breast cancer risk. JAMA 1983;249:445–6
   PubMedGoogle Scholar
• Cibula D, Gompel A, Mueck AO, et al. Hormonal contraception and risk of cancer. Hum Reprod Update 2010;16:631–50
   PubMed Web of Science ®Google Scholar
• Fabre A, Fournier A, Mesrine S, et al. Oral progestagens before menopause and breast cancer risk. Br J Cancer 2007;96:841–4
   PubMed Web of Science ®Google Scholar
• Plu-Bureau G, Lê MG, Sitruk-Ware R, Thalabard JC, Mauvais-Jarvis P. Progestogen use and decreased risk of breast cancer in a cohort study of premenopausal women with benign breast disease. Br J Cancer 1994;70:270–7
   PubMed Web of Science ®Google Scholar
• Foidart J-M, Desreux J, Pintiaux A, Gompel A. Hormone therapy and breast cancer risk. Climacteric 2007;10(Suppl 2):54–61
   PubMedGoogle Scholar
• Gompel A, Santen RJ. Hormone therapy and breast cancer risk 10 years after the WHI. Climacteric 2012;15:241–9
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321–33
   PubMed Web of Science ®Google Scholar
• Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 2004;291:1701–12
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Anderson GL, Gass M, et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 2010;304:1684–92
   PubMed Web of Science ®Google Scholar
• Anderson GL, Chlebowski RT, Aragaki AK, et al. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women’s Health Initiative randomised placebo-controlled trial. Lancet Oncol 2012;13:476–86
   PubMed Web of Science ®Google Scholar
• Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women’s Health Initiative randomized trials. JAMA 2017;318:927–38
   PubMed Web of Science ®Google Scholar
• Maximov PY, Abderrahman B, Curpan RF, Hawsawi YM, Fan P, Jordan VC. A unifying biology of sex steroid-induced apoptosis in prostate and breast cancers. Endocr Relat Cancer 2018;25:R83–113
   PubMed Web of Science ®Google Scholar
• Hickey M, McNamara HC, Mishra GD. Menopausal estrogen therapy and breast cancer mortality. JAMA 2018;319:193
   PubMed Web of Science ®Google Scholar
• Manson JE, Aragaki AK, Rossouw JE. Menopausal estrogen therapy and breast cancer mortality-reply. JAMA 2018;319:193–4
   PubMed Web of Science ®Google Scholar
• Chen WY, Manson JE, Hankinson SE, et al. Unopposed estrogen therapy and the risk of invasive breast cancer. Arch Intern Med 2006;166:1027–32
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Anderson GL. Menopausal hormone therapy and breast cancer mortality: clinical implications. Ther Adv Drug Saf 2015;6:45–56
   PubMed Web of Science ®Google Scholar
• Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 2005;114:448–54
   PubMed Web of Science ®Google Scholar
• Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008;107:103–11
   PubMed Web of Science ®Google Scholar
• Espié M, Daures JP, Chevallier T, Mares P, Micheletti MC, De Reilhac P. Breast cancer incidence and hormone replacement therapy: results from the MISSION study, prospective phase. Gynecol Endocrinol 2007;23:391–7
   PubMed Web of Science ®Google Scholar
• Cordina-Duverger E, Truong T, Anger A, et al. Risk of breast cancer by type of menopausal hormone therapy: a case-control study among post-menopausal women in France. PLoS One 2013;8:e78016
   PubMed Web of Science ®Google Scholar
• Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estradiol-progestogen therapy. Obstet Gynecol 2009;113:65–73
   PubMed Web of Science ®Google Scholar
• Fournier A, Mesrine S, Dossus L, Boutron-Ruault M-C, Clavel-Chapelon F, Chabbert-Buffet N. Risk of breast cancer after stopping menopausal hormone therapy in the E3N cohort. Breast Cancer Res Treat 2014;145:535–43
   PubMed Web of Science ®Google Scholar
• Schneider C, Jick SS, Meier CR. Risk of gynecological cancers in users of estradiol/dydrogesterone or other HRT preparations. Climacteric 2009;12:514–24
   PubMed Web of Science ®Google Scholar
• Courtin A, Communal L, Vilasco M, et al. Glucocorticoid receptor activity discriminates between progesterone and medroxyprogesterone acetate effects in breast cells. Breast Cancer Res Treat 2012;131:49–63
   PubMed Web of Science ®Google Scholar
• Stanczyk FZ, Hapgood JP, Winer S, Mishell DR. Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects. Endocr Rev 2013;34:171–208
   PubMed Web of Science ®Google Scholar
• Vilasco M, Communal L, Mourra N, Courtin A, Forgez P, Gompel A. Glucocorticoid receptor and breast cancer. Breast Cancer Res Treat 2011;130:1–10
   PubMed Web of Science ®Google Scholar
• Pan D, Kocherginsky M, Conzen SD. Activation of the glucocorticoid receptor is associated with poor prognosis in estrogen receptor-negative breast cancer. Cancer Res 2011;71:6360–70
   PubMed Web of Science ®Google Scholar
• Vilasco M, Communal L, Hugon-Rodin J, et al. Loss of glucocorticoid receptor activation is a hallmark of BRCA1-mutated breast tissue. Breast Cancer Res Treat 2013;142:283–96
   PubMed Web of Science ®Google Scholar
• Daemen A, Manning G. HER2 is not a cancer subtype but rather a pan-cancer event and is highly enriched in AR-driven breast tumors. Breast Cancer Res 2018;20:8
   PubMed Web of Science ®Google Scholar
• Rangel N, Rondon-Lagos M, Annaratone L, et al. The role of the AR/ER ratio in ER-positive breast cancer patients. Endocr Relat Cancer 2018;25:163–72
   PubMed Web of Science ®Google Scholar
• Traina TA, Miller K, Yardley DA, et al. Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer. J Clin Oncol 2018;36:884–90
   PubMed Web of Science ®Google Scholar
• Leehy KA, Regan Anderson TM, Daniel AR, Lange CA, Ostrander JH. Modifications to glucocorticoid and progesterone receptors alter cell fate in breast cancer. J Mol Endocrinol 2016;56:R99–114
   PubMed Web of Science ®Google Scholar
• Carroll JS, Hickey TE, Tarulli GA, Williams M, Tilley WD. Deciphering the divergent roles of progestogens in breast cancer. Nat Rev Cancer 2017;17:54–64
   PubMed Web of Science ®Google Scholar
• Russo J, Ao X, Grill C, Russo IH. Pattern of distribution of cells positive for estrogen receptor alpha and progesterone receptor in relation to proliferating cells in the mammary gland. Breast Cancer Res Treat 1999;53:217–27
   PubMed Web of Science ®Google Scholar
• Mohammed H, Russell IA, Stark R, et al. Progesterone receptor modulates ERα action in breast cancer. Nature 2015;523:313–17
   PubMed Web of Science ®Google Scholar
• Prior JC, Hitchcock CL. Progesterone for hot flush and night sweat treatment–effectiveness for severe vasomotor symptoms and lack of withdrawal rebound. Gynecol Endocrinol 2012;28(Suppl 2):7–11
   PubMedGoogle Scholar
• Hitchcock CL, Prior JC. Oral micronized progesterone for vasomotor symptoms–a placebo-controlled randomized trial in healthy postmenopausal women. Menopause 2012;19:886–93
   PubMed Web of Science ®Google Scholar
• Badwe R, Hawaldar R, Parmar V, et al. Single-injection depot progesterone before surgery and survival in women with operable breast cancer: a randomized controlled trial. J Clin Oncol 2011;29:2845–51
   PubMed Web of Science ®Google Scholar
• Chatterjee S, Chaubal R, Maitra A, et al. Pre-operative progesterone benefits operable breast cancer patients by modulating surgical stress. Breast Cancer Res Treat 2018. Epub ahead of print
   PubMed Web of Science ®Google Scholar
• Tan IJ, Peeva E, Zandman-Goddard G. Hormonal modulation of the immune system – A spotlight on the role of progestogens. Autoimmun Rev 2015;14:536–42
   PubMed Web of Science ®Google Scholar